Drugs interactions for Glyxambi®
- 127 Major drug interactions (including ingredients like Abametapir, Abemaciclib, Acalabrutinib)
- 995 Moderate drug interactions (including ingredients like Abatacept, Abiraterone, Abrocitinib)
- 182 Minor drug interactions (including ingredients like Abaloparatide, Acetazolamide, Acetyl sulfisoxazole)
1304 interactions for Glyxambi®The serum concentration of Linagliptin can be increased when it is combined with Abametapir.The serum concentration of Abemaciclib can be increased when it is combined with Linagliptin.The metabolism of Acalabrutinib can be decreased when combined with Linagliptin.The metabolism of Alectinib can be decreased when combined with Linagliptin.The metabolism of Alpelisib can be decreased when combined with Linagliptin.The metabolism of Aminophylline can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Amiodarone.The metabolism of Linagliptin can be decreased when combined with Atazanavir.The serum concentration of Axitinib can be increased when it is combined with Linagliptin.The serum concentration of Bendamustine can be increased when it is combined with Linagliptin.The metabolism of Bicalutamide can be decreased when combined with Linagliptin.The serum concentration of Binimetinib can be increased when it is combined with Linagliptin.The serum concentration of Bortezomib can be increased when it is combined with Linagliptin.The metabolism of Brigatinib can be decreased when combined with Linagliptin.The metabolism of Busulfan can be decreased when combined with Linagliptin.The metabolism of Cabazitaxel can be decreased when combined with Linagliptin.The serum concentration of Cabergoline can be increased when it is combined with Linagliptin.The metabolism of Carbamazepine can be decreased when combined with Linagliptin.The serum concentration of Carfilzomib can be increased when it is combined with Linagliptin.The metabolism of Cariprazine can be decreased when combined with Linagliptin.The serum concentration of Ceritinib can be increased when it is combined with Linagliptin.The serum concentration of Cisplatin can be increased when it is combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Clarithromycin.The serum concentration of Clofarabine can be increased when it is combined with Linagliptin.The metabolism of Clomipramine can be decreased when combined with Linagliptin.The metabolism of Clonidine can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Conivaptan.The metabolism of Copanlisib can be decreased when combined with Linagliptin.The serum concentration of Crizotinib can be increased when it is combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Curcumin.The metabolism of Cyclophosphamide can be decreased when combined with Linagliptin.The serum concentration of Cyclosporine can be increased when it is combined with Linagliptin.The serum concentration of Dacomitinib can be increased when it is combined with Linagliptin.The serum concentration of Dactinomycin can be increased when it is combined with Linagliptin.The serum concentration of Dalfampridine can be increased when it is combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Danazol.The metabolism of Linagliptin can be decreased when combined with Darunavir.The serum concentration of Dasatinib can be increased when it is combined with Linagliptin.The serum concentration of Defactinib can be increased when it is combined with Linagliptin.The metabolism of Dihydroergotamine can be decreased when combined with Linagliptin.The metabolism of Docetaxel can be decreased when combined with Linagliptin.The metabolism of Dofetilide can be decreased when combined with Linagliptin.The metabolism of Dronedarone can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Efavirenz.The serum concentration of Elacestrant can be increased when it is combined with Linagliptin.The metabolism of Eliglustat can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Elvitegravir.The metabolism of Enasidenib can be decreased when combined with Linagliptin.The metabolism of Entrectinib can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Ergotamine.The metabolism of Erlotinib can be decreased when combined with Linagliptin.The serum concentration of Etoposide can be increased when it is combined with Linagliptin.The metabolism of Flibanserin can be decreased when combined with Linagliptin.The serum concentration of Gemcitabine can be increased when it is combined with Linagliptin.The serum concentration of Gentamicin can be increased when it is combined with Linagliptin.The metabolism of Idelalisib can be decreased when combined with Linagliptin.The metabolism of Ifosfamide can be decreased when combined with Linagliptin.The serum concentration of Imipramine can be increased when it is combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Indinavir.The metabolism of Infigratinib can be decreased when combined with Linagliptin.The metabolism of Irinotecan can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Itraconazole.The metabolism of Ivabradine can be decreased when combined with Linagliptin.The metabolism of Ixabepilone can be decreased when combined with Linagliptin.The metabolism of Ixazomib can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Ketoconazole.The metabolism of Linagliptin can be decreased when combined with Levoketoconazole.The metabolism of Lomitapide can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Lonafarnib.The metabolism of Linagliptin can be decreased when combined with Lopinavir.The metabolism of Linagliptin can be decreased when combined with Methimazole.The metabolism of Methotrexate can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Midostaurin.The metabolism of Linagliptin can be increased when combined with Mitotane.The metabolism of Linagliptin can be decreased when combined with Nefazodone.The metabolism of Linagliptin can be decreased when combined with Nelfinavir.The metabolism of Neratinib can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Nilotinib.The serum concentration of Nortriptyline can be increased when it is combined with Linagliptin.The serum concentration of Omaveloxolone can be increased when it is combined with Linagliptin.The serum concentration of Osimertinib can be increased when it is combined with Linagliptin.The serum concentration of Oxaliplatin can be increased when it is combined with Linagliptin.The metabolism of Paclitaxel can be decreased when combined with Linagliptin.The serum concentration of Pacritinib can be increased when it is combined with Linagliptin.The metabolism of Palbociclib can be decreased when combined with Linagliptin.The serum concentration of Panobinostat can be increased when it is combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Pentobarbital.The metabolism of Pexidartinib can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Phenobarbital.The metabolism of Pimavanserin can be increased when combined with Linagliptin.The metabolism of Pimozide can be decreased when combined with Linagliptin.The serum concentration of Pomalidomide can be increased when it is combined with Linagliptin.The metabolism of Ponatinib can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Posaconazole.The serum concentration of Pretomanid can be increased when it is combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Primidone.The serum concentration of Procainamide can be increased when it is combined with Linagliptin.The serum concentration of Quinidine can be increased when it is combined with Linagliptin.The serum concentration of Regorafenib can be increased when it is combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Ribociclib.The metabolism of Linagliptin can be increased when combined with Rifapentine.The serum concentration of Rimegepant can be increased when it is combined with Linagliptin.The serum concentration of Romidepsin can be increased when it is combined with Linagliptin.The metabolism of Ruxolitinib can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Saquinavir.The serum concentration of Selumetinib can be increased when it is combined with Linagliptin.The excretion of Silodosin can be decreased when combined with Linagliptin.The risk or severity of adverse effects can be increased when Linagliptin is combined with Siponimod.The serum concentration of Sirolimus can be increased when it is combined with Linagliptin.The metabolism of Sorafenib can be decreased when combined with Linagliptin.The metabolism of Sunitinib can be decreased when combined with Linagliptin.The metabolism of Tamoxifen can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Telithromycin.The serum concentration of Temsirolimus can be increased when it is combined with Linagliptin.The metabolism of Teniposide can be decreased when combined with Linagliptin.The serum concentration of Tepotinib can be increased when it is combined with Linagliptin.The metabolism of Theophylline can be decreased when combined with Linagliptin.The metabolism of Thiotepa can be decreased when combined with Linagliptin.The serum concentration of Tolvaptan can be increased when it is combined with Linagliptin.The metabolism of Trabectedin can be decreased when combined with Linagliptin.The serum concentration of Trastuzumab emtansine can be increased when it is combined with Linagliptin.The serum concentration of Trimipramine can be increased when it is combined with Linagliptin.The metabolism of Vandetanib can be decreased when combined with Linagliptin.The serum concentration of Venetoclax can be increased when it is combined with Linagliptin.The serum concentration of Vinblastine can be increased when it is combined with Linagliptin.The metabolism of Vinorelbine can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Voriconazole.The metabolism of Linagliptin can be increased when combined with Abatacept.The metabolism of Linagliptin can be decreased when combined with Abiraterone.The serum concentration of Linagliptin can be increased when it is combined with Abrocitinib.The risk or severity of hypoglycemia can be increased when Acarbose is combined with Linagliptin.Empagliflozin may increase the hypoglycemic activities of Acarbose.The therapeutic efficacy of Linagliptin can be increased when used in combination with Acebutolol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Acebutolol.The serum concentration of Acenocoumarol can be increased when it is combined with Linagliptin.The metabolism of Acetaminophen can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Acetazolamide.The risk or severity of adverse effects can be increased when Linagliptin is combined with Acetylcholine.The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Linagliptin is combined with Acyclovir.The metabolism of Adagrasib can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Adalimumab.The serum concentration of Afatinib can be increased when it is combined with Linagliptin.The metabolism of Albendazole can be decreased when combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Empagliflozin.The metabolism of Linagliptin can be decreased when combined with Aldesleukin.The metabolism of Alfentanil can be decreased when combined with Linagliptin.The metabolism of Alfuzosin can be decreased when combined with Linagliptin.The metabolism of Aliskiren can be decreased when combined with Linagliptin.The metabolism of Almotriptan can be decreased when combined with Linagliptin.The metabolism of Alogliptin can be decreased when combined with Linagliptin.Empagliflozin may increase the hypoglycemic activities of Alogliptin.The metabolism of Alosetron can be decreased when combined with Linagliptin.The metabolism of Alprazolam can be decreased when combined with Linagliptin.The risk or severity of angioedema can be increased when Alteplase is combined with Linagliptin.The serum concentration of Linagliptin can be increased when it is combined with Amantadine.The metabolism of Ambrisentan can be decreased when combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Empagliflozin.The serum concentration of Linagliptin can be increased when it is combined with Amiloride.Aminosalicylic acid may increase the hypoglycemic activities of Linagliptin.Aminosalicylic acid may increase the hypoglycemic activities of Empagliflozin.The risk or severity of hypoglycemia can be increased when Amiodarone is combined with Empagliflozin.Amitriptyline may decrease the hypoglycemic activities of Linagliptin.Amitriptyline may decrease the hypoglycemic activities of Empagliflozin.The metabolism of Amlodipine can be decreased when combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Empagliflozin.The metabolism of Linagliptin can be increased when combined with Amobarbital.Amobarbital may increase the hypotensive activities of Empagliflozin.Amoxapine may decrease the hypoglycemic activities of Linagliptin.Amoxapine may decrease the hypoglycemic activities of Empagliflozin.The metabolism of Linagliptin can be increased when combined with Anakinra.The metabolism of Antipyrine can be decreased when combined with Linagliptin.The serum concentration of Linagliptin can be decreased when it is combined with Apalutamide.The metabolism of Apixaban can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Apremilast.The metabolism of Linagliptin can be decreased when combined with Aprepitant.The metabolism of Aripiprazole can be decreased when combined with Linagliptin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Aripiprazole.The metabolism of Aripiprazole lauroxil can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Armodafinil.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Arsenic trioxide.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Arsenic trioxide.The metabolism of Artemether can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Articaine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Articaine.The serum concentration of Linagliptin can be increased when it is combined with Asciminib.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Asenapine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Asenapine.The metabolism of Asunaprevir can be decreased when combined with Linagliptin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Atazanavir.The therapeutic efficacy of Linagliptin can be increased when used in combination with Atenolol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Atenolol.The metabolism of Atogepant can be decreased when combined with Linagliptin.The metabolism of Atorvastatin can be decreased when combined with Linagliptin.The metabolism of Atovaquone can be decreased when combined with Linagliptin.The metabolism of Avacopan can be decreased when combined with Linagliptin.The metabolism of Avanafil can be decreased when combined with Linagliptin.The metabolism of Avapritinib can be decreased when combined with Linagliptin.The metabolism of Avatrombopag can be decreased when combined with Linagliptin.The metabolism of Avutometinib can be decreased when combined with Linagliptin.The metabolism of Azelastine can be decreased when combined with Linagliptin.The risk or severity of angioedema can be increased when Azilsartan medoxomil is combined with Linagliptin.The metabolism of Azithromycin can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Baclofen.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Baclofen.Balsalazide may increase the hypoglycemic activities of Linagliptin.Balsalazide may increase the hypoglycemic activities of Empagliflozin.The metabolism of Baricitinib can be decreased when combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Empagliflozin.The metabolism of Bedaquiline can be decreased when combined with Linagliptin.The serum concentration of Belinostat can be increased when it is combined with Linagliptin.The metabolism of Belumosudil can be decreased when combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Benazepril is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Benazepril is combined with Empagliflozin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Bendroflumethiazide.The metabolism of Benzphetamine can be decreased when combined with Linagliptin.The serum concentration of Berotralstat can be increased when it is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Empagliflozin.The therapeutic efficacy of Linagliptin can be increased when used in combination with Betaxolol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Betaxolol.The serum concentration of Betrixaban can be increased when it is combined with Linagliptin.Bexagliflozin may increase the hypoglycemic activities of Linagliptin.Empagliflozin may increase the hypoglycemic activities of Bexagliflozin.The metabolism of Linagliptin can be increased when combined with Bexarotene.The metabolism of Bictegravir can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Bimekizumab.Bismuth subsalicylate may increase the hypoglycemic activities of Linagliptin.Bismuth subsalicylate may increase the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Linagliptin can be increased when used in combination with Bisoprolol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Bisoprolol.The metabolism of Linagliptin can be increased when combined with Bosentan.The serum concentration of Bosutinib can be increased when it is combined with Linagliptin.The serum concentration of Brentuximab vedotin can be increased when it is combined with Linagliptin.The metabolism of Brexpiprazole can be decreased when combined with Linagliptin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Brexpiprazole.The metabolism of Brivaracetam can be decreased when combined with Linagliptin.The metabolism of Bromocriptine can be decreased when combined with Linagliptin.Empagliflozin may increase the hypoglycemic activities of Bromocriptine.The risk or severity of hyperglycemia can be increased when Budesonide is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Budesonide is combined with Empagliflozin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Bumetanide.The metabolism of Bupivacaine can be decreased when combined with Linagliptin.The metabolism of Buprenorphine can be decreased when combined with Linagliptin.The excretion of Linagliptin can be decreased when combined with Bupropion.The metabolism of Buspirone can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Butalbital.Butalbital may increase the hypotensive activities of Empagliflozin.The metabolism of Cabozantinib can be decreased when combined with Linagliptin.The metabolism of Calcitriol can be decreased when combined with Linagliptin.Canagliflozin may increase the hypoglycemic activities of Linagliptin.Canagliflozin may increase the hypoglycemic activities of Empagliflozin.The metabolism of Linagliptin can be increased when combined with Canakinumab.The metabolism of Cannabidiol can be decreased when combined with Linagliptin.The serum concentration of Capivasertib can be increased when it is combined with Linagliptin.The metabolism of Capmatinib can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Capsaicin.The risk or severity of angioedema can be increased when Linagliptin is combined with Captopril.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Captopril.The therapeutic efficacy of Linagliptin can be increased when used in combination with Carvedilol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Carvedilol.The metabolism of Celecoxib can be decreased when combined with Linagliptin.The serum concentration of Linagliptin can be decreased when it is combined with Cenobamate.The metabolism of Cephalexin can be decreased when combined with Linagliptin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ceritinib.The metabolism of Linagliptin can be increased when combined with Certolizumab pegol.The metabolism of Cevimeline can be decreased when combined with Linagliptin.The metabolism of Chenodeoxycholic acid can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Chloramphenicol.The metabolism of Chloroquine can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Chlorothiazide.The metabolism of Chlorpheniramine can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Chlorpromazine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Chlorpromazine.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Chlorthalidone.The metabolism of Chlorzoxazone can be decreased when combined with Linagliptin.The metabolism of Cholecalciferol can be decreased when combined with Linagliptin.The serum concentration of Linagliptin can be increased when it is combined with Choline.Choline salicylate may increase the hypoglycemic activities of Linagliptin.Choline salicylate may increase the hypoglycemic activities of Empagliflozin.The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Empagliflozin.The metabolism of Cilostazol can be decreased when combined with Linagliptin.The serum concentration of Linagliptin can be increased when it is combined with Cimetidine.The metabolism of Cinacalcet can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be increased when used in combination with Ciprofloxacin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Ciprofloxacin.The risk or severity of hypoglycemia can be increased when Citalopram is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Citalopram is combined with Empagliflozin.The metabolism of Clevidipine can be decreased when combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Empagliflozin.The metabolism of Clindamycin can be decreased when combined with Linagliptin.The metabolism of Clobazam can be decreased when combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Empagliflozin.The serum concentration of Clomifene can be increased when it is combined with Linagliptin.Clomipramine may decrease the hypoglycemic activities of Empagliflozin.The metabolism of Clonazepam can be decreased when combined with Linagliptin.The metabolism of Clopidogrel can be decreased when combined with Linagliptin.The metabolism of Clorazepic acid can be decreased when combined with Linagliptin.The serum concentration of Clozapine can be increased when it is combined with Linagliptin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Clozapine.The metabolism of Cobicistat can be decreased when combined with Linagliptin.The metabolism of Cobimetinib can be decreased when combined with Linagliptin.The metabolism of Codeine can be decreased when combined with Linagliptin.The serum concentration of Colchicine can be increased when it is combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Conjugated estrogens.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Conjugated estrogens.The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Empagliflozin.The metabolism of Crinecerfont can be decreased when combined with Linagliptin.The metabolism of Cyclobenzaprine can be decreased when combined with Linagliptin.The risk or severity of adverse effects can be increased when Linagliptin is combined with Cytarabine.The serum concentration of Dabigatran etexilate can be increased when it is combined with Linagliptin.The serum concentration of Linagliptin can be decreased when it is combined with Dabrafenib.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dabrafenib.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Danazol.The serum concentration of Linagliptin can be increased when it is combined with Danicopan.Dapagliflozin may increase the hypoglycemic activities of Linagliptin.Dapagliflozin may increase the hypoglycemic activities of Empagliflozin.The metabolism of Dapsone can be decreased when combined with Linagliptin.The serum concentration of Daptomycin can be increased when it is combined with Linagliptin.The metabolism of Daridorexant can be decreased when combined with Linagliptin.The metabolism of Darifenacin can be decreased when combined with Linagliptin.The metabolism of Darolutamide can be decreased when combined with Linagliptin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Darunavir.The metabolism of Dasabuvir can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Daunorubicin.The metabolism of Linagliptin can be increased when combined with Deferasirox.The serum concentration of Deflazacort can be increased when it is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Empagliflozin.The therapeutic efficacy of Linagliptin can be increased when used in combination with Delafloxacin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Delafloxacin.Desipramine may decrease the hypoglycemic activities of Linagliptin.Desipramine may decrease the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Desogestrel.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Desogestrel.The risk or severity of hyperglycemia can be increased when Desonide is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Desonide is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Empagliflozin.The metabolism of Deuruxolitinib can be decreased when combined with Linagliptin.The metabolism of Deutetrabenazine can be decreased when combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Empagliflozin.The serum concentration of Linagliptin can be decreased when it is combined with Dexamethasone acetate.The risk or severity of hyperglycemia can be increased when Dexamethasone acetate is combined with Empagliflozin.The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Linagliptin.The metabolism of Dexlansoprazole can be decreased when combined with Linagliptin.The metabolism of Dextromethorphan can be decreased when combined with Linagliptin.The metabolism of Dextropropoxyphene can be decreased when combined with Linagliptin.The metabolism of Diazepam can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Diazoxide.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Diazoxide.The metabolism of Diclofenac can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Dicloxacillin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Dienogest.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dienogest.The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Empagliflozin.Diflunisal may increase the hypoglycemic activities of Linagliptin.Diflunisal may increase the hypoglycemic activities of Empagliflozin.The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Empagliflozin.Linagliptin may decrease the excretion rate of Digoxin which could result in a higher serum level.The metabolism of Dihydro-alpha-ergocryptine can be decreased when combined with Linagliptin.The metabolism of Dihydrocodeine can be decreased when combined with Linagliptin.The metabolism of Dihydroergocornine can be decreased when combined with Linagliptin.The metabolism of Dihydroergocristine can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Diltiazem.The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Empagliflozin.The metabolism of Linagliptin can be decreased when combined with Dimethyl sulfoxide.The serum concentration of Linagliptin can be increased when it is combined with Dinoprostone.The serum concentration of Linagliptin can be increased when it is combined with Diosmin.The serum concentration of Linagliptin can be increased when it is combined with Diphenhydramine.The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Linagliptin.Empagliflozin may increase the hypoglycemic activities of Disopyramide.The metabolism of Disulfiram can be decreased when combined with Linagliptin.The metabolism of Dolasetron can be decreased when combined with Linagliptin.The serum concentration of Dolutegravir can be increased when it is combined with Linagliptin.The metabolism of Donepezil can be decreased when combined with Linagliptin.The serum concentration of Linagliptin can be increased when it is combined with Dopamine.The metabolism of Doravirine can be decreased when combined with Linagliptin.The metabolism of Doxazosin can be decreased when combined with Linagliptin.Doxepin may decrease the hypoglycemic activities of Linagliptin.Doxepin may decrease the hypoglycemic activities of Empagliflozin.The serum concentration of Doxorubicin can be increased when it is combined with Linagliptin.The serum concentration of Dronabinol can be increased when it is combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Drospirenone.The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Dulaglutide.Empagliflozin may increase the hypoglycemic activities of Dulaglutide.The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Linagliptin.The metabolism of Duvelisib can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Echinacea.The serum concentration of Edoxaban can be increased when it is combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Elafibranor.The serum concentration of Elagolix can be increased when it is combined with Linagliptin.The metabolism of Elbasvir can be decreased when combined with Linagliptin.The metabolism of Eletriptan can be decreased when combined with Linagliptin.The serum concentration of Elexacaftor can be increased when it is combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Emapalumab.The risk or severity of angioedema can be increased when Linagliptin is combined with Enalapril.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Enalapril.The risk or severity of angioedema can be increased when Linagliptin is combined with Enalaprilat.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Enalaprilat.The serum concentration of Encorafenib can be increased when it is combined with Linagliptin.The metabolism of Enfortumab vedotin can be decreased when combined with Linagliptin.The serum concentration of Linagliptin can be decreased when it is combined with Enzalutamide.The serum concentration of Linagliptin can be increased when it is combined with Epcoritamab.The metabolism of Epinastine can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Epinephrine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Epinephrine.The metabolism of Eplerenone can be decreased when combined with Linagliptin.The risk or severity of angioedema can be increased when Eprosartan is combined with Linagliptin.The metabolism of Eravacycline can be decreased when combined with Linagliptin.The serum concentration of Linagliptin can be increased when it is combined with Erdafitinib.Ertugliflozin may increase the hypoglycemic activities of Linagliptin.Empagliflozin may increase the hypoglycemic activities of Ertugliflozin.The serum concentration of Linagliptin can be increased when it is combined with Erythromycin.The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Empagliflozin.The metabolism of Esketamine can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Eslicarbazepine acetate.The metabolism of Esomeprazole can be decreased when combined with Linagliptin.The metabolism of Estazolam can be decreased when combined with Linagliptin.The metabolism of Esterified estrogens can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Estetrol.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Estetrol.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Estradiol.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Estradiol.The metabolism of Estradiol acetate can be decreased when combined with Linagliptin.The metabolism of Estradiol cypionate can be decreased when combined with Linagliptin.The metabolism of Estradiol valerate can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Estrone sulfate.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Estrone sulfate.The metabolism of Eszopiclone can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Etacrynic acid.The metabolism of Linagliptin can be increased when combined with Etanercept.The metabolism of Ethanol can be decreased when combined with Linagliptin.Ethanol may increase the hypotensive activities of Empagliflozin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Ethinylestradiol.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ethinylestradiol.The metabolism of Ethosuximide can be decreased when combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Empagliflozin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Ethynodiol diacetate.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ethynodiol diacetate.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Etonogestrel.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Etonogestrel.The serum concentration of Etrasimod can be increased when it is combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Etravirine.The metabolism of Everolimus can be decreased when combined with Linagliptin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Everolimus.The metabolism of Exemestane can be decreased when combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Exenatide is combined with Linagliptin.Empagliflozin may increase the hypoglycemic activities of Exenatide.The serum concentration of Linagliptin can be increased when it is combined with Famotidine.The serum concentration of Linagliptin can be increased when it is combined with Fedratinib.The metabolism of Felbamate can be decreased when combined with Linagliptin.The metabolism of Felodipine can be decreased when combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Felodipine is combined with Empagliflozin.The metabolism of Fenofibrate can be decreased when combined with Linagliptin.The metabolism of Fentanyl can be decreased when combined with Linagliptin.The metabolism of Fesoterodine can be decreased when combined with Linagliptin.The metabolism of Fexinidazole can be decreased when combined with Linagliptin.The serum concentration of Fexofenadine can be increased when it is combined with Linagliptin.The metabolism of Finasteride can be decreased when combined with Linagliptin.The serum concentration of Finerenone can be increased when it is combined with Linagliptin.The metabolism of Fish oil can be decreased when combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Fluconazole.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Fluconazole.The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Empagliflozin.The metabolism of Flurazepam can be decreased when combined with Linagliptin.The metabolism of Flutamide can be decreased when combined with Linagliptin.The serum concentration of Fluticasone furoate can be increased when it is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Empagliflozin.The metabolism of Fluvastatin can be decreased when combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Linagliptin is combined with Formoterol.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Fosamprenavir.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Fosamprenavir.The metabolism of Fosaprepitant can be decreased when combined with Linagliptin.The risk or severity of angioedema can be increased when Linagliptin is combined with Fosinopril.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Fosinopril.The metabolism of Fosnetupitant can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Fosphenytoin.The metabolism of Fostamatinib can be decreased when combined with Linagliptin.The metabolism of Fostemsavir can be decreased when combined with Linagliptin.The metabolism of Fruquintinib can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Furosemide.The metabolism of Linagliptin can be decreased when combined with Fusidic acid.The serum concentration of Futibatinib can be increased when it is combined with Linagliptin.The metabolism of Galantamine can be decreased when combined with Linagliptin.The risk or severity of adverse effects can be increased when Linagliptin is combined with Ganciclovir.The therapeutic efficacy of Linagliptin can be increased when used in combination with Gatifloxacin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Gatifloxacin.The metabolism of Gefitinib can be decreased when combined with Linagliptin.The metabolism of Gemfibrozil can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be increased when used in combination with Gemifloxacin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Gemifloxacin.The metabolism of Linagliptin can be increased when combined with Genistein.The serum concentration of Gepirone can be increased when it is combined with Linagliptin.The metabolism of Gepotidacin can be decreased when combined with Linagliptin.The metabolism of Gestodene can be decreased when combined with Linagliptin.The metabolism of Gilteritinib can be decreased when combined with Linagliptin.The metabolism of Glasdegib can be decreased when combined with Linagliptin.The serum concentration of Glecaprevir can be increased when it is combined with Linagliptin.Linagliptin may increase the hypoglycemic activities of Glimepiride.Empagliflozin may increase the hypoglycemic activities of Glimepiride.Linagliptin may increase the hypoglycemic activities of Glipizide.Empagliflozin may increase the hypoglycemic activities of Glipizide.The serum concentration of Linagliptin can be increased when it is combined with Glofitamab.Linagliptin may increase the hypoglycemic activities of Glyburide.Empagliflozin may increase the hypoglycemic activities of Glyburide.The metabolism of Linagliptin can be increased when combined with Glycerol phenylbutyrate.The metabolism of Linagliptin can be increased when combined with Golimumab.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Goserelin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Goserelin.The metabolism of Granisetron can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Grapefruit.The metabolism of Grazoprevir can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Griseofulvin.The metabolism of Guanfacine can be decreased when combined with Linagliptin.The serum concentration of Linagliptin can be increased when it is combined with Guanidine.The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Empagliflozin.The serum concentration of Haloperidol can be increased when it is combined with Linagliptin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Haloperidol.The serum concentration of Linagliptin can be increased when it is combined with Histamine.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Histrelin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Histrelin.The metabolism of Linagliptin can be decreased when combined with Hydralazine.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Hydrochlorothiazide.The metabolism of Hydrocodone can be decreased when combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Empagliflozin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Hydroflumethiazide.The therapeutic efficacy of Linagliptin can be increased when used in combination with Hydroxychloroquine.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Hydroxychloroquine.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Hydroxyprogesterone caproate.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Hydroxyprogesterone caproate.The metabolism of Hydroxyzine can be decreased when combined with Linagliptin.The metabolism of Ibrexafungerp can be decreased when combined with Linagliptin.The metabolism of Ibrutinib can be decreased when combined with Linagliptin.The metabolism of Ibuprofen can be decreased when combined with Linagliptin.The risk or severity of angioedema can be increased when Icatibant is combined with Linagliptin.The metabolism of Iloperidone can be decreased when combined with Linagliptin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Iloperidone.The metabolism of Imatinib can be decreased when combined with Linagliptin.Imipramine may decrease the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Indapamide.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Indinavir.The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Empagliflozin.The metabolism of Linagliptin can be increased when combined with Infliximab.The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin aspart.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin aspart.The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin degludec.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin degludec.The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin detemir.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin detemir.The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin glargine.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin glargine.The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin glulisine.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin glulisine.The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin human.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin human.The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin lispro.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin lispro.The metabolism of Ipecac can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Irbesartan.The serum concentration of Linagliptin can be increased when it is combined with Isavuconazonium.Isocarboxazid may increase the orthostatic hypotensive activities of Empagliflozin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Isoniazid.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Isoniazid.The metabolism of Isotretinoin can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Isradipine.The risk or severity of hypoglycemia can be increased when Isradipine is combined with Empagliflozin.The metabolism of Istradefylline can be decreased when combined with Linagliptin.The metabolism of Ivacaftor can be decreased when combined with Linagliptin.The metabolism of Ivermectin can be decreased when combined with Linagliptin.The metabolism of Ivosidenib can be decreased when combined with Linagliptin.The metabolism of Ketamine can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be increased when used in combination with Labetalol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Labetalol.The metabolism of Lacosamide can be decreased when combined with Linagliptin.The serum concentration of Lamivudine can be increased when it is combined with Linagliptin.The serum concentration of Linagliptin can be increased when it is combined with Lamotrigine.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Lanreotide.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lanreotide.The metabolism of Lansoprazole can be decreased when combined with Linagliptin.The metabolism of Lapatinib can be decreased when combined with Linagliptin.The metabolism of Larotrectinib can be decreased when combined with Linagliptin.The serum concentration of Linagliptin can be increased when it is combined with Lasmiditan.The metabolism of Lazertinib can be decreased when combined with Linagliptin.The serum concentration of Ledipasvir can be increased when it is combined with Linagliptin.Linagliptin may decrease the excretion rate of Lefamulin which could result in a higher serum level.The metabolism of Lemborexant can be decreased when combined with Linagliptin.The metabolism of Lenacapavir can be decreased when combined with Linagliptin.The serum concentration of Lenvatinib can be increased when it is combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Letermovir.The metabolism of Letrozole can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Leuprolide.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Leuprolide.The serum concentration of Levamlodipine can be increased when it is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Empagliflozin.The metabolism of Levocetirizine can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be increased when used in combination with Levofloxacin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Levofloxacin.The metabolism of Levomenthol can be decreased when combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Empagliflozin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Levonorgestrel.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Levonorgestrel.The metabolism of Lidocaine can be decreased when combined with Linagliptin.Linezolid may increase the orthostatic hypotensive activities of Empagliflozin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Liothyronine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Liothyronine.The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Liraglutide is combined with Linagliptin.Empagliflozin may increase the hypoglycemic activities of Liraglutide.The risk or severity of angioedema can be increased when Linagliptin is combined with Lisinopril.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Lisinopril.The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Lixisenatide.Empagliflozin may increase the hypoglycemic activities of Lixisenatide.The therapeutic efficacy of Linagliptin can be increased when used in combination with Lomefloxacin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Lomefloxacin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Lonapegsomatropin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lonapegsomatropin.The serum concentration of Loncastuximab tesirine can be increased when it is combined with Linagliptin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lopinavir.The metabolism of Loratadine can be decreased when combined with Linagliptin.The serum concentration of Linagliptin can be decreased when it is combined with Lorlatinib.The metabolism of Losartan can be decreased when combined with Linagliptin.The metabolism of Lovastatin can be decreased when combined with Linagliptin.The serum concentration of Linagliptin can be increased when it is combined with Loxapine.The serum concentration of Linagliptin can be decreased when it is combined with Lumacaftor.The serum concentration of Lumateperone can be increased when it is combined with Linagliptin.The metabolism of Lumefantrine can be decreased when combined with Linagliptin.The metabolism of Lurasidone can be decreased when combined with Linagliptin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lurasidone.The serum concentration of Lurbinectedin can be increased when it is combined with Linagliptin.The serum concentration of Lusutrombopag can be increased when it is combined with Linagliptin.The metabolism of Macimorelin can be decreased when combined with Linagliptin.The metabolism of Macitentan can be decreased when combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Empagliflozin.The serum concentration of Mannitol can be increased when it is combined with Linagliptin.The metabolism of Maraviroc can be decreased when combined with Linagliptin.The metabolism of Maribavir can be decreased when combined with Linagliptin.The serum concentration of Mavacamten can be increased when it is combined with Linagliptin.The metabolism of Mavorixafor can be decreased when combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Mecasermin is combined with Linagliptin.Empagliflozin may increase the hypoglycemic activities of Mecasermin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Medroxyprogesterone acetate.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.The risk or severity of hyperglycemia can be increased when Medrysone is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Medrysone is combined with Empagliflozin.The metabolism of Mefloquine can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Megestrol acetate.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Megestrol acetate.The metabolism of Meloxicam can be decreased when combined with Linagliptin.The serum concentration of Memantine can be increased when it is combined with Linagliptin.The metabolism of Meperidine can be decreased when combined with Linagliptin.Mesalazine may increase the hypoglycemic activities of Linagliptin.Mesalazine may increase the hypoglycemic activities of Empagliflozin.The metabolism of Methadone can be decreased when combined with Linagliptin.Methohexital may increase the hypotensive activities of Empagliflozin.The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Empagliflozin.Methyl salicylate may increase the hypoglycemic activities of Linagliptin.Methyl salicylate may increase the hypoglycemic activities of Empagliflozin.The serum concentration of Methylene blue can be increased when it is combined with Linagliptin.Methylene blue may increase the orthostatic hypotensive activities of Empagliflozin.The metabolism of Methylergometrine can be decreased when combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Empagliflozin.The metabolism of Methyltestosterone can be decreased when combined with Linagliptin.The metabolism of Metoclopramide can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Metolazone.The therapeutic efficacy of Linagliptin can be increased when used in combination with Metoprolol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Metoprolol.The metabolism of Linagliptin can be decreased when combined with Metronidazole.The metabolism of Linagliptin can be increased when combined with Metyrapone.The metabolism of Mexiletine can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Miconazole.The serum concentration of Midazolam can be increased when it is combined with Linagliptin.The serum concentration of Linagliptin can be decreased when it is combined with Mifepristone.Empagliflozin may increase the hypoglycemic activities of Mifepristone.The risk or severity of hypoglycemia can be increased when Miglitol is combined with Linagliptin.Empagliflozin may increase the hypoglycemic activities of Miglitol.The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Empagliflozin.The metabolism of Mirabegron can be decreased when combined with Linagliptin.The metabolism of Mirtazapine can be decreased when combined with Linagliptin.The metabolism of Mitapivat can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Modafinil.The risk or severity of angioedema can be increased when Linagliptin is combined with Moexipril.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Moexipril.The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Empagliflozin.The metabolism of Montelukast can be decreased when combined with Linagliptin.The metabolism of Morphine can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be increased when used in combination with Moxifloxacin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Moxifloxacin.The metabolism of Mycophenolate mofetil can be decreased when combined with Linagliptin.The metabolism of Nabilone can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be increased when used in combination with Nadolol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Nadolol.The metabolism of Linagliptin can be increased when combined with Nafcillin.The serum concentration of Naloxegol can be increased when it is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Nateglinide is combined with Linagliptin.Empagliflozin may increase the hypoglycemic activities of Nateglinide.The therapeutic efficacy of Linagliptin can be increased when used in combination with Nebivolol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Nebivolol.The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nelfinavir.The metabolism of Netupitant can be decreased when combined with Linagliptin.The metabolism of Nevirapine can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Niacin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Niacin.The metabolism of Linagliptin can be decreased when combined with Nicardipine.The risk or severity of hypoglycemia can be increased when Nicardipine is combined with Empagliflozin.The serum concentration of Linagliptin can be increased when it is combined with Nicotine.The metabolism of Nifedipine can be decreased when combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Nifedipine is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nilotinib.The metabolism of Nimodipine can be decreased when combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Empagliflozin.The metabolism of Nintedanib can be decreased when combined with Linagliptin.The metabolism of Nirmatrelvir can be decreased when combined with Linagliptin.The serum concentration of Nirogacestat can be increased when it is combined with Linagliptin.The metabolism of Nisoldipine can be decreased when combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Empagliflozin.The metabolism of Norelgestromin can be decreased when combined with Linagliptin.The serum concentration of Linagliptin can be increased when it is combined with Norepinephrine.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Norethisterone.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Norethisterone.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Norgestimate.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Norgestimate.The metabolism of Norgestrel can be decreased when combined with Linagliptin.Nortriptyline may decrease the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Octreotide.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Octreotide.The therapeutic efficacy of Linagliptin can be increased when used in combination with Ofloxacin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Ofloxacin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Olanzapine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Olanzapine.The metabolism of Olaparib can be decreased when combined with Linagliptin.The serum concentration of Oliceridine can be increased when it is combined with Linagliptin.Olsalazine may increase the hypoglycemic activities of Linagliptin.Olsalazine may increase the hypoglycemic activities of Empagliflozin.The metabolism of Olutasidenib can be decreased when combined with Linagliptin.The serum concentration of Omadacycline can be increased when it is combined with Linagliptin.The serum concentration of Ombitasvir can be increased when it is combined with Linagliptin.The metabolism of Ondansetron can be decreased when combined with Linagliptin.The metabolism of Opium can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Oritavancin.The metabolism of Orphenadrine can be decreased when combined with Linagliptin.The metabolism of Osilodrostat can be decreased when combined with Linagliptin.The metabolism of Ospemifene can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Oxcarbazepine.The metabolism of Oxybutynin can be decreased when combined with Linagliptin.The metabolism of Oxycodone can be decreased when combined with Linagliptin.The metabolism of Oxymorphone can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Paliperidone.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Paliperidone.The metabolism of Palonosetron can be decreased when combined with Linagliptin.The serum concentration of Palovarotene can be increased when it is combined with Linagliptin.The risk or severity of adverse effects can be increased when Linagliptin is combined with Pancuronium.The metabolism of Pantoprazole can be decreased when combined with Linagliptin.The metabolism of Parecoxib can be decreased when combined with Linagliptin.The metabolism of Paricalcitol can be decreased when combined with Linagliptin.The metabolism of Paritaprevir can be decreased when combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Empagliflozin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Pasireotide.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pasireotide.The serum concentration of Pazopanib can be increased when it is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Empagliflozin.The metabolism of Pemigatinib can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Pentamidine.Empagliflozin may increase the hypoglycemic activities of Pentamidine.Pentobarbital may increase the hypotensive activities of Empagliflozin.The metabolism of Perampanel can be decreased when combined with Linagliptin.The risk or severity of angioedema can be increased when Linagliptin is combined with Perindopril.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Perindopril.Phenelzine may increase the orthostatic hypotensive activities of Empagliflozin.Phenobarbital may increase the hypotensive activities of Empagliflozin.The serum concentration of Linagliptin can be increased when it is combined with Phenoxybenzamine.The therapeutic efficacy of Linagliptin can be increased when used in combination with Phentermine.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Phentermine.The metabolism of Linagliptin can be increased when combined with Phenytoin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Phenytoin.The serum concentration of Pibrentasvir can be increased when it is combined with Linagliptin.The metabolism of Pinaverium can be decreased when combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Empagliflozin.The therapeutic efficacy of Linagliptin can be increased when used in combination with Pindolol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Pindolol.The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Linagliptin.Empagliflozin may increase the hypoglycemic activities of Pioglitazone.The serum concentration of Linagliptin can be increased when it is combined with Piperine.The metabolism of Pirtobrutinib can be decreased when combined with Linagliptin.The serum concentration of Linagliptin can be decreased when it is combined with Pitolisant.The metabolism of Polatuzumab vedotin can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Polythiazide.The metabolism of Ponesimod can be decreased when combined with Linagliptin.The serum concentration of Pralsetinib can be increased when it is combined with Linagliptin.The serum concentration of Pramipexole can be increased when it is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Pramlintide is combined with Linagliptin.Empagliflozin may increase the hypoglycemic activities of Pramlintide.The metabolism of Prasterone can be decreased when combined with Linagliptin.The serum concentration of Pravastatin can be increased when it is combined with Linagliptin.The metabolism of Praziquantel can be decreased when combined with Linagliptin.The serum concentration of Prazosin can be increased when it is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Empagliflozin.The serum concentration of Linagliptin can be decreased when it is combined with Prednisolone phosphate.The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Prednisone is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Prednisone is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Empagliflozin.The metabolism of Pregnenolone can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Primaquine.Primidone may increase the hypotensive activities of Empagliflozin.The serum concentration of Linagliptin can be increased when it is combined with Probenecid.Procaine may increase the orthostatic hypotensive activities of Empagliflozin.Procarbazine may increase the orthostatic hypotensive activities of Empagliflozin.The metabolism of Prochlorperazine can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Progesterone.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Progesterone.The therapeutic efficacy of Linagliptin can be increased when used in combination with Propafenone.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Propafenone.The therapeutic efficacy of Linagliptin can be increased when used in combination with Propranolol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Propranolol.Protriptyline may decrease the hypoglycemic activities of Linagliptin.Protriptyline may decrease the hypoglycemic activities of Empagliflozin.The serum concentration of Prucalopride can be increased when it is combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Pseudoephedrine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pseudoephedrine.The metabolism of Quazepam can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Quetiapine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Quetiapine.The risk or severity of angioedema can be increased when Linagliptin is combined with Quinapril.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Quinapril.The risk or severity of hypoglycemia can be increased when Quinine is combined with Linagliptin.Empagliflozin may increase the hypoglycemic activities of Quinine.The metabolism of Quizartinib can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Raloxifene.The metabolism of Ramelteon can be decreased when combined with Linagliptin.The risk or severity of angioedema can be increased when Linagliptin is combined with Ramipril.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Ramipril.The serum concentration of Linagliptin can be increased when it is combined with Ranitidine.The serum concentration of Ranolazine can be increased when it is combined with Linagliptin.Rasagiline may increase the orthostatic hypotensive activities of Empagliflozin.The serum concentration of Relugolix can be increased when it is combined with Linagliptin.The metabolism of Remdesivir can be decreased when combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Linagliptin.Empagliflozin may increase the hypoglycemic activities of Repaglinide.The serum concentration of Repotrectinib can be increased when it is combined with Linagliptin.The serum concentration of Linagliptin can be increased when it is combined with Reserpine.The metabolism of Retapamulin can be decreased when combined with Linagliptin.The serum concentration of Revefenacin can be increased when it is combined with Linagliptin.The metabolism of Revumenib can be decreased when combined with Linagliptin.The metabolism of Rifabutin can be decreased when combined with Linagliptin.The serum concentration of Linagliptin can be decreased when it is combined with Rifampicin.The serum concentration of Rifaximin can be increased when it is combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Rilonacept.The metabolism of Rilpivirine can be decreased when combined with Linagliptin.The metabolism of Riociguat can be decreased when combined with Linagliptin.The metabolism of Ripretinib can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Risperidone.The serum concentration of Linagliptin can be increased when it is combined with Ritlecitinib.The serum concentration of Linagliptin can be increased when it is combined with Ritonavir.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ritonavir.The metabolism of Rivaroxaban can be decreased when combined with Linagliptin.The risk or severity of adverse effects can be increased when Linagliptin is combined with Rocuronium.The serum concentration of Roflumilast can be increased when it is combined with Linagliptin.The metabolism of Rolapitant can be decreased when combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Rosiglitazone is combined with Linagliptin.Empagliflozin may increase the hypoglycemic activities of Rosiglitazone.The metabolism of Rosuvastatin can be decreased when combined with Linagliptin.The metabolism of Rotigotine can be decreased when combined with Linagliptin.The metabolism of Rucaparib can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Rufinamide.The risk or severity of angioedema can be increased when Linagliptin is combined with Sacubitril.The metabolism of Safinamide can be decreased when combined with Linagliptin.Safinamide may increase the orthostatic hypotensive activities of Empagliflozin.Salicylic acid may increase the hypoglycemic activities of Linagliptin.Salicylic acid may increase the hypoglycemic activities of Empagliflozin.The metabolism of Salmeterol can be decreased when combined with Linagliptin.The metabolism of Samidorphan can be decreased when combined with Linagliptin.The serum concentration of Linagliptin can be increased when it is combined with Sapropterin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Saquinavir.The serum concentration of Linagliptin can be increased when it is combined with Sarecycline.The metabolism of Linagliptin can be increased when combined with Sarilumab.The serum concentration of Linagliptin can be decreased when it is combined with Satralizumab.The risk or severity of hypoglycemia can be increased when Saxagliptin is combined with Linagliptin.Empagliflozin may increase the hypoglycemic activities of Saxagliptin.The metabolism of Scopolamine can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Secobarbital.Secobarbital may increase the hypotensive activities of Empagliflozin.The metabolism of Linagliptin can be increased when combined with Secukinumab.The metabolism of Selegiline can be decreased when combined with Linagliptin.Selegiline may increase the orthostatic hypotensive activities of Empagliflozin.The metabolism of Selexipag can be decreased when combined with Linagliptin.The metabolism of Selinexor can be decreased when combined with Linagliptin.The metabolism of Selpercatinib can be decreased when combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Semaglutide.Empagliflozin may increase the hypoglycemic activities of Semaglutide.The risk or severity of hypoglycemia can be increased when Sertraline is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Sertraline is combined with Empagliflozin.The metabolism of Sildenafil can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Siltuximab.The metabolism of Simvastatin can be decreased when combined with Linagliptin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Sirolimus.The risk or severity of hypoglycemia can be increased when Sitagliptin is combined with Linagliptin.Empagliflozin may increase the hypoglycemic activities of Sitagliptin.The risk or severity of hypotension can be increased when Sodium ferric gluconate complex is combined with Empagliflozin.The serum concentration of Sofosbuvir can be increased when it is combined with Linagliptin.The metabolism of Solifenacin can be decreased when combined with Linagliptin.The serum concentration of Solriamfetol can be increased when it is combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Somapacitan.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Somapacitan.Somatotropin may decrease the hypoglycemic activities of Linagliptin.Somatotropin may decrease the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Somatrogon.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Somatrogon.The metabolism of Sonidegib can be decreased when combined with Linagliptin.The serum concentration of Linagliptin can be increased when it is combined with Sotagliflozin.Empagliflozin may increase the hypoglycemic activities of Sotagliflozin.The risk or severity of hypoglycemia can be increased when Sotalol is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Sotalol is combined with Empagliflozin.The serum concentration of Linagliptin can be decreased when it is combined with Sotorasib.The metabolism of Sparsentan can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Stiripentol.The metabolism of Sufentanil can be decreased when combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Sulfadiazine is combined with Linagliptin.Empagliflozin may increase the hypoglycemic activities of Sulfadiazine.The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Linagliptin.Empagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.Sulfasalazine may increase the hypoglycemic activities of Linagliptin.Sulfasalazine may increase the hypoglycemic activities of Empagliflozin.Empagliflozin may increase the hypoglycemic activities of Sunitinib.The metabolism of Suvorexant can be decreased when combined with Linagliptin.The metabolism of Suzetrigine can be decreased when combined with Linagliptin.The metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Linagliptin.The metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Linagliptin.The serum concentration of Tacrolimus can be increased when it is combined with Linagliptin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Tacrolimus.The metabolism of Tadalafil can be decreased when combined with Linagliptin.The serum concentration of Linagliptin can be increased when it is combined with Tafenoquine.The metabolism of Tamsulosin can be decreased when combined with Linagliptin.The metabolism of Tasimelteon can be decreased when combined with Linagliptin.The metabolism of Tazemetostat can be decreased when combined with Linagliptin.The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Tecovirimat.The serum concentration of Tegaserod can be increased when it is combined with Linagliptin.The risk or severity of angioedema can be increased when Telmisartan is combined with Linagliptin.The serum concentration of Linagliptin can be decreased when it is combined with Telotristat ethyl.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Temsirolimus.The risk or severity of angioedema can be increased when Tenecteplase is combined with Linagliptin.The serum concentration of Tenofovir alafenamide can be increased when it is combined with Linagliptin.The serum concentration of Tenofovir disoproxil can be increased when it is combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Teprotumumab.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Teprotumumab.The metabolism of Terbinafine can be decreased when combined with Linagliptin.The metabolism of Testosterone can be decreased when combined with Linagliptin.The metabolism of Testosterone cypionate can be decreased when combined with Linagliptin.The metabolism of Testosterone enanthate can be decreased when combined with Linagliptin.The metabolism of Testosterone propionate can be decreased when combined with Linagliptin.The metabolism of Tetracycline can be decreased when combined with Linagliptin.The metabolism of Tezacaftor can be decreased when combined with Linagliptin.The metabolism of Thalidomide can be decreased when combined with Linagliptin.The serum concentration of Linagliptin can be increased when it is combined with Thiamine.Thyroid, porcine may decrease the hypoglycemic activities of Linagliptin.Thyroid, porcine may decrease the hypoglycemic activities of Empagliflozin.Thyrotropin alfa may decrease the hypoglycemic activities of Linagliptin.Thyrotropin alfa may decrease the hypoglycemic activities of Empagliflozin.The metabolism of Tiagabine can be decreased when combined with Linagliptin.The metabolism of Ticagrelor can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be increased when used in combination with Timolol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Timolol.The metabolism of Tinidazole can be decreased when combined with Linagliptin.The metabolism of Tiotropium can be decreased when combined with Linagliptin.The serum concentration of Linagliptin can be decreased when it is combined with Tipranavir.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Tipranavir.The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Tirzepatide.Empagliflozin may increase the hypoglycemic activities of Tirzepatide.The metabolism of Tisotumab vedotin can be decreased when combined with Linagliptin.The serum concentration of Tivozanib can be increased when it is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Empagliflozin.The metabolism of Linagliptin can be increased when combined with Tocilizumab.The metabolism of Tocofersolan can be decreased when combined with Linagliptin.The metabolism of Tocopherol can be decreased when combined with Linagliptin.The metabolism of Tofacitinib can be decreased when combined with Linagliptin.Linagliptin may increase the hypoglycemic activities of Tolazamide.Empagliflozin may increase the hypoglycemic activities of Tolazamide.The metabolism of Tolterodine can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Topiramate.The serum concentration of Topotecan can be increased when it is combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Torasemide.The metabolism of Toremifene can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Tovorafenib.The metabolism of Tramadol can be decreased when combined with Linagliptin.The risk or severity of angioedema can be increased when Linagliptin is combined with Trandolapril.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Trandolapril.Tranylcypromine may increase the orthostatic hypotensive activities of Empagliflozin.The serum concentration of Linagliptin can be decreased when it is combined with Trazodone.The metabolism of Linagliptin can be decreased when combined with Treosulfan.The metabolism of Tretinoin can be decreased when combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Empagliflozin.The metabolism of Triazolam can be decreased when combined with Linagliptin.The metabolism of Triclabendazole can be decreased when combined with Linagliptin.The serum concentration of Trilaciclib can be increased when it is combined with Linagliptin.The metabolism of Trimethoprim can be decreased when combined with Linagliptin.Trimipramine may decrease the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Triptorelin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Triptorelin.Trolamine salicylate may increase the hypoglycemic activities of Linagliptin.Trolamine salicylate may increase the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Linagliptin can be increased when used in combination with Trovafloxacin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Trovafloxacin.Tucatinib may decrease the excretion rate of Linagliptin which could result in a higher serum level.The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Empagliflozin.The serum concentration of Ubrogepant can be increased when it is combined with Linagliptin.The metabolism of Ulipristal can be decreased when combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Empagliflozin.The serum concentration of Umeclidinium can be increased when it is combined with Linagliptin.The metabolism of Upadacitinib can be decreased when combined with Linagliptin.The risk or severity of angioedema can be increased when Urokinase is combined with Linagliptin.The metabolism of Valbenazine can be decreased when combined with Linagliptin.The metabolism of Valdecoxib can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be decreased when combined with Valproic acid.The risk or severity of angioedema can be increased when Valsartan is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Vamorolone is combined with Linagliptin.The risk or severity of hyperglycemia can be increased when Vamorolone is combined with Empagliflozin.The metabolism of Vardenafil can be decreased when combined with Linagliptin.The metabolism of Velpatasvir can be decreased when combined with Linagliptin.The serum concentration of Linagliptin can be increased when it is combined with Vemurafenib.The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Empagliflozin.The metabolism of Linagliptin can be decreased when combined with Verapamil.The risk or severity of hypoglycemia can be increased when Verapamil is combined with Empagliflozin.The metabolism of Vilanterol can be decreased when combined with Linagliptin.The metabolism of Vilazodone can be decreased when combined with Linagliptin.The serum concentration of Linagliptin can be increased when it is combined with Vimseltinib.The excretion of Vincristine can be decreased when combined with Linagliptin.The metabolism of Vitamin D can be decreased when combined with Linagliptin.The metabolism of Vitamin E can be decreased when combined with Linagliptin.The metabolism of Voclosporin can be decreased when combined with Linagliptin.The metabolism of Vonoprazan can be decreased when combined with Linagliptin.The metabolism of Vorapaxar can be decreased when combined with Linagliptin.The metabolism of Linagliptin can be increased when combined with Vorasidenib.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Vorinostat.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Vorinostat.The metabolism of Vortioxetine can be decreased when combined with Linagliptin.The serum concentration of Voxelotor can be increased when it is combined with Linagliptin.The metabolism of Voxilaprevir can be decreased when combined with Linagliptin.The serum concentration of Warfarin can be increased when it is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Empagliflozin.The metabolism of Linagliptin can be decreased when combined with Zafirlukast.The metabolism of Zaleplon can be decreased when combined with Linagliptin.The metabolism of Zanubrutinib can be decreased when combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Linagliptin.The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Empagliflozin.The metabolism of Zidovudine can be decreased when combined with Linagliptin.The metabolism of Zileuton can be decreased when combined with Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Ziprasidone.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ziprasidone.The metabolism of Zolpidem can be decreased when combined with Linagliptin.The metabolism of Zonisamide can be decreased when combined with Linagliptin.The metabolism of Zuranolone can be decreased when combined with Linagliptin.The risk or severity of adverse effects can be increased when Abaloparatide is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Acetazolamide.The therapeutic efficacy of Linagliptin can be increased when used in combination with Acetyl sulfisoxazole.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Acetyl sulfisoxazole.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Albuterol.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Albuterol.The risk or severity of adverse effects can be increased when Aldesleukin is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Aliskiren is combined with Empagliflozin.Empagliflozin may increase the hypotensive activities of Ambrisentan.The risk or severity of adverse effects can be increased when Amifostine is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Amiloride.The risk or severity of adverse effects can be increased when Amphotericin B is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Apomorphine is combined with Empagliflozin.Empagliflozin may increase the hypotensive activities of Aprocitentan.The serum concentration of Linagliptin can be increased when it is combined with Arimoclomol.Aripiprazole lauroxil may increase the hypotensive activities of Empagliflozin.The risk or severity of hypotension can be increased when Avanafil is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Bendroflumethiazide.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Bosentan.The risk or severity of adverse effects can be increased when Bretylium is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Brinzolamide.Empagliflozin may increase the diuretic activities of Bromotheophylline.Empagliflozin may increase the diuretic activities of Bumetanide.The risk or severity of adverse effects can be increased when Bupivacaine is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Celecoxib.Empagliflozin may increase the diuretic activities of Chlorothiazide.Empagliflozin may increase the diuretic activities of Chlorthalidone.The risk or severity of adverse effects can be increased when Clofarabine is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Clonidine is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Conivaptan.The metabolism of Linagliptin can be decreased when combined with Dalfopristin.Empagliflozin may increase the hypotensive activities of Dasiglucagon.The risk or severity of adverse effects can be increased when Desflurane is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Empagliflozin.The therapeutic efficacy of Linagliptin can be increased when used in combination with Diclofenamide.Empagliflozin may increase the diuretic activities of Diclofenamide.The risk or severity of adverse effects can be increased when Empagliflozin is combined with Dinutuximab.The risk or severity of adverse effects can be increased when Dipyridamole is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Dorzolamide.The risk or severity of adverse effects can be increased when Doxazosin is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Drospirenone.The risk or severity of orthostatic hypotension and syncope can be increased when Empagliflozin is combined with Duloxetine.The serum concentration of Ensartinib can be increased when it is combined with Linagliptin.Empagliflozin may increase the diuretic activities of Eplerenone.The risk or severity of adverse effects can be increased when Epoprostenol is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Eprosartan is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Esmolol is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Etacrynic acid.The metabolism of Linagliptin can be decreased when combined with Ethambutol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Fedratinib.The risk or severity of adverse effects can be increased when Fenoldopam is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Finerenone.Fluoxymesterone may increase the hypoglycemic activities of Linagliptin.Fluoxymesterone may increase the hypoglycemic activities of Empagliflozin.The risk or severity of hypotension can be increased when Fostamatinib is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Furosemide.The metabolism of Linagliptin can be decreased when combined with Ginkgo biloba.The risk or severity of adverse effects can be increased when Guanfacine is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Hydralazine is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Hydrochlorothiazide.Empagliflozin may increase the diuretic activities of Hydroflumethiazide.The risk or severity of adverse effects can be increased when Iloprost is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Indapamide.The risk or severity of adverse effects can be increased when Irbesartan is combined with Empagliflozin.Isocarboxazid may increase the hypoglycemic activities of Linagliptin.The risk or severity of adverse effects can be increased when Isoflurane is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Isosorbide.The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Isosorbide mononitrate is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Empagliflozin.The risk or severity of thrombocytopenia can be increased when Linagliptin is combined with Ketotifen.The risk or severity of thrombocytopenia can be increased when Empagliflozin is combined with Ketotifen.The serum concentration of Linagliptin can be increased when it is combined with L-Acetylleucine.Empagliflozin may increase the hypotensive activities of Landiolol.The risk or severity of hypotension and orthostatic hypotension can be increased when Empagliflozin is combined with Levodopa.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Levothyroxine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Levothyroxine.Linezolid may increase the hypoglycemic activities of Linagliptin.The therapeutic efficacy of Linagliptin can be decreased when used in combination with Lithium carbonate.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lithium carbonate.The risk or severity of adverse effects can be increased when Lofexidine is combined with Empagliflozin.The excretion of Loperamide can be decreased when combined with Linagliptin.The risk or severity of adverse effects can be increased when Losartan is combined with Empagliflozin.Empagliflozin may increase the hypotensive activities of Macitentan.Empagliflozin may increase the diuretic activities of Mannitol.The risk or severity of adverse effects can be increased when Mecamylamine is combined with Empagliflozin.The therapeutic efficacy of Linagliptin can be increased when used in combination with Methazolamide.Empagliflozin may increase the diuretic activities of Methazolamide.The risk or severity of adverse effects can be increased when Methyldopa is combined with Empagliflozin.Methyltestosterone may increase the hypoglycemic activities of Empagliflozin.Empagliflozin may increase the diuretic activities of Metolazone.The metabolism of Linagliptin can be increased when combined with Metreleptin.Empagliflozin may increase the hypotensive activities of Metyrosine.The risk or severity of adverse effects can be increased when Minoxidil is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Mitapivat.The risk or severity of adverse effects can be increased when Morphine is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Nabilone is combined with Empagliflozin.Nandrolone decanoate may increase the hypoglycemic activities of Linagliptin.Nandrolone decanoate may increase the hypoglycemic activities of Empagliflozin.The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Nitroprusside is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Empagliflozin is combined with Nitrous acid.The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Olmesartan is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Empagliflozin is combined with Opicapone.Oxandrolone may increase the hypoglycemic activities of Linagliptin.Oxandrolone may increase the hypoglycemic activities of Empagliflozin.Oxymetholone may increase the hypoglycemic activities of Linagliptin.Oxymetholone may increase the hypoglycemic activities of Empagliflozin.The risk or severity of adverse effects can be increased when Paclitaxel is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Papaverine is combined with Empagliflozin.Phenelzine may increase the hypoglycemic activities of Linagliptin.The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Phentolamine is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Polythiazide.Empagliflozin may increase the diuretic activities of Potassium.Empagliflozin may increase the diuretic activities of Potassium cation.Empagliflozin may increase the diuretic activities of Potassium citrate.The risk or severity of adverse effects can be increased when Pramipexole is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Prazosin is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Probenecid.Procaine may increase the hypoglycemic activities of Linagliptin.Procarbazine may increase the hypoglycemic activities of Linagliptin.The metabolism of Linagliptin can be decreased when combined with Propofol.The risk or severity of adverse effects can be increased when Propofol is combined with Empagliflozin.The metabolism of Linagliptin can be decreased when combined with Quinupristin.Rasagiline may increase the hypoglycemic activities of Linagliptin.The risk or severity of adverse effects can be increased when Remifentanil is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Reserpine is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Riociguat is combined with Empagliflozin.Empagliflozin may increase the hypotensive activities of Risperidone.The risk or severity of adverse effects can be increased when Ropinirole is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Ropivacaine is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Rosuvastatin.The risk or severity of adverse effects can be increased when Rotigotine is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Empagliflozin is combined with Sacubitril.Empagliflozin may increase the hypotensive activities of Selexipag.The risk or severity of adverse effects can be increased when Sevoflurane is combined with Empagliflozin.The risk or severity of hypotension can be increased when Sildenafil is combined with Empagliflozin.Empagliflozin may increase the hypotensive activities of Sotatercept.Empagliflozin may increase the diuretic activities of Spironolactone.The risk or severity of adverse effects can be increased when Sufentanil is combined with Empagliflozin.The therapeutic efficacy of Linagliptin can be increased when used in combination with Sulfamethizole.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sulfamethizole.The therapeutic efficacy of Linagliptin can be increased when used in combination with Sumatriptan.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sumatriptan.Empagliflozin may increase the hypotensive activities of Tadalafil.The serum concentration of Talazoparib can be increased when it is combined with Linagliptin.The risk or severity of adverse effects can be increased when Tamsulosin is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Telmisartan is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Terazosin is combined with Empagliflozin.Testosterone may increase the hypoglycemic activities of Empagliflozin.Testosterone cypionate may increase the hypoglycemic activities of Empagliflozin.Testosterone enanthate may increase the hypoglycemic activities of Empagliflozin.Testosterone propionate may increase the hypoglycemic activities of Empagliflozin.Testosterone undecanoate may increase the hypoglycemic activities of Linagliptin.Testosterone undecanoate may increase the hypoglycemic activities of Empagliflozin.The risk or severity of adverse effects can be increased when Thalidomide is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Thioridazine is combined with Empagliflozin.The excretion of Tipiracil can be decreased when combined with Linagliptin.The risk or severity of adverse effects can be increased when Tizanidine is combined with Empagliflozin.Empagliflozin may increase the hypotensive activities of Tocopherylquinone.The risk or severity of adverse effects can be increased when Tolcapone is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Tolvaptan.Empagliflozin may increase the diuretic activities of Torasemide.Tranylcypromine may increase the hypoglycemic activities of Linagliptin.Empagliflozin may increase the hypotensive activities of Treprostinil.Empagliflozin may increase the diuretic activities of Triamterene.The metabolism of Linagliptin can be decreased when combined with Trofinetide.The serum concentration of Linagliptin can be increased when it is combined with Vadadustat.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Valdecoxib.The risk or severity of adverse effects can be increased when Valsartan is combined with Empagliflozin.The risk or severity of hypotension can be increased when Vardenafil is combined with Empagliflozin.The excretion of Varenicline can be decreased when combined with Linagliptin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Vemurafenib.The risk or severity of adverse effects can be increased when Empagliflozin is combined with Vericiguat.The metabolism of Linagliptin can be decreased when combined with Viloxazine.Empagliflozin may increase the diuretic activities of Zonisamide.
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and Glyxambi®.
Abametapir
Abemaciclib
Acalabrutinib
Alectinib
Alpelisib
Aminophylline
Amiodarone
Atazanavir
Axitinib
Bendamustine
Bicalutamide
Binimetinib
Bortezomib
Brigatinib
Busulfan
Cabazitaxel
Cabergoline
Carbamazepine
Carfilzomib
Cariprazine
Ceritinib
Cisplatin
Clarithromycin
Clofarabine
Clomipramine
Clonidine
Conivaptan
Copanlisib
Crizotinib
Curcumin
Cyclophosphamide
Cyclosporine
Dacomitinib
Dactinomycin
Dalfampridine
Danazol
Darunavir
Dasatinib
Defactinib
Dihydroergotamine
Docetaxel
Dofetilide
Dronedarone
Efavirenz
Elacestrant
Eliglustat
Elvitegravir
Enasidenib
Entrectinib
Ergotamine
Erlotinib
Etoposide
Flibanserin
Gemcitabine
Gentamicin
Idelalisib
Ifosfamide
Imipramine
Indinavir
Infigratinib
Irinotecan
Itraconazole
Ivabradine
Ixabepilone
Ixazomib
Ketoconazole
Levoketoconazole
Lomitapide
Lonafarnib
Lopinavir
Methimazole
Methotrexate
Midostaurin
Mitotane
Nefazodone
Nelfinavir
Neratinib
Nilotinib
Nortriptyline
Omaveloxolone
Osimertinib
Oxaliplatin
Paclitaxel
Pacritinib
Palbociclib
Panobinostat
Pentobarbital
Pexidartinib
Phenobarbital
Pimavanserin
Pimozide
Pomalidomide
Ponatinib
Posaconazole
Pretomanid
Primidone
Procainamide
Quinidine
Regorafenib
Ribociclib
Rifapentine
Rimegepant
Romidepsin
Ruxolitinib
Saquinavir
Selumetinib
Silodosin
Siponimod
Sirolimus
Sorafenib
Sunitinib
Tamoxifen
Telithromycin
Temsirolimus
Teniposide
Tepotinib
Theophylline
Thiotepa
Tolvaptan
Trabectedin
Trastuzumab emtansine
Trimipramine
Vandetanib
Venetoclax
Vinblastine
Vinorelbine
Voriconazole
Abatacept
Abiraterone
Abrocitinib
Acarbose
Acarbose
Acebutolol
Acebutolol
Acenocoumarol
Acetaminophen
Acetazolamide
Acetylcholine
Acetylsalicylic acid
Acetylsalicylic acid
Acyclovir
Adagrasib
Adalimumab
Afatinib
Albendazole
Alclometasone
Alclometasone
Aldesleukin
Alfentanil
Alfuzosin
Aliskiren
Almotriptan
Alogliptin
Alogliptin
Alosetron
Alprazolam
Alteplase
Amantadine
Ambrisentan
Amcinonide
Amcinonide
Amiloride
Aminosalicylic acid
Aminosalicylic acid
Amiodarone
Amitriptyline
Amitriptyline
Amlodipine
Amlodipine
Amobarbital
Amobarbital
Amoxapine
Amoxapine
Anakinra
Antipyrine
Apalutamide
Apixaban
Apremilast
Aprepitant
Aripiprazole
Aripiprazole
Aripiprazole lauroxil
Armodafinil
Arsenic trioxide
Arsenic trioxide
Artemether
Articaine
Articaine
Asciminib
Asenapine
Asenapine
Asunaprevir
Atazanavir
Atenolol
Atenolol
Atogepant
Atorvastatin
Atovaquone
Avacopan
Avanafil
Avapritinib
Avatrombopag
Avutometinib
Azelastine
Azilsartan medoxomil
Azithromycin
Baclofen
Baclofen
Balsalazide
Balsalazide
Baricitinib
Beclomethasone dipropionate
Beclomethasone dipropionate
Bedaquiline
Belinostat
Belumosudil
Benazepril
Benazepril
Bendroflumethiazide
Benzphetamine
Berotralstat
Betamethasone
Betamethasone
Betaxolol
Betaxolol
Betrixaban
Bexagliflozin
Bexagliflozin
Bexarotene
Bictegravir
Bimekizumab
Bismuth subsalicylate
Bismuth subsalicylate
Bisoprolol
Bisoprolol
Bosentan
Bosutinib
Brentuximab vedotin
Brexpiprazole
Brexpiprazole
Brivaracetam
Bromocriptine
Bromocriptine
Budesonide
Budesonide
Bumetanide
Bupivacaine
Buprenorphine
Bupropion
Buspirone
Butalbital
Butalbital
Cabozantinib
Calcitriol
Canagliflozin
Canagliflozin
Canakinumab
Cannabidiol
Capivasertib
Capmatinib
Capsaicin
Captopril
Captopril
Carvedilol
Carvedilol
Celecoxib
Cenobamate
Cephalexin
Ceritinib
Certolizumab pegol
Cevimeline
Chenodeoxycholic acid
Chloramphenicol
Chloroquine
Chlorothiazide
Chlorpheniramine
Chlorpromazine
Chlorpromazine
Chlorthalidone
Chlorzoxazone
Cholecalciferol
Choline
Choline salicylate
Choline salicylate
Ciclesonide
Ciclesonide
Cilostazol
Cimetidine
Cinacalcet
Ciprofloxacin
Ciprofloxacin
Citalopram
Citalopram
Clevidipine
Clevidipine
Clindamycin
Clobazam
Clobetasol propionate
Clobetasol propionate
Clocortolone
Clocortolone
Clomifene
Clomipramine
Clonazepam
Clopidogrel
Clorazepic acid
Clozapine
Clozapine
Cobicistat
Cobimetinib
Codeine
Colchicine
Conjugated estrogens
Conjugated estrogens
Corticotropin
Corticotropin
Cortisone acetate
Cortisone acetate
Crinecerfont
Cyclobenzaprine
Cytarabine
Dabigatran etexilate
Dabrafenib
Dabrafenib
Danazol
Danicopan
Dapagliflozin
Dapagliflozin
Dapsone
Daptomycin
Daridorexant
Darifenacin
Darolutamide
Darunavir
Dasabuvir
Daunorubicin
Deferasirox
Deflazacort
Deflazacort
Delafloxacin
Delafloxacin
Desipramine
Desipramine
Desogestrel
Desogestrel
Desonide
Desonide
Desoximetasone
Desoximetasone
Desvenlafaxine
Desvenlafaxine
Deuruxolitinib
Deutetrabenazine
Dexamethasone
Dexamethasone
Dexamethasone acetate
Dexamethasone acetate
Dexchlorpheniramine maleate
Dexlansoprazole
Dextromethorphan
Dextropropoxyphene
Diazepam
Diazoxide
Diazoxide
Diclofenac
Dicloxacillin
Dienogest
Dienogest
Diflorasone
Diflorasone
Diflunisal
Diflunisal
Difluprednate
Difluprednate
Digoxin
Dihydro-alpha-ergocryptine
Dihydrocodeine
Dihydroergocornine
Dihydroergocristine
Diltiazem
Diltiazem
Dimethyl sulfoxide
Dinoprostone
Diosmin
Diphenhydramine
Disopyramide
Disopyramide
Disulfiram
Dolasetron
Dolutegravir
Donepezil
Dopamine
Doravirine
Doxazosin
Doxepin
Doxepin
Doxorubicin
Dronabinol
Drospirenone
Dulaglutide
Dulaglutide
Duloxetine
Duvelisib
Echinacea
Edoxaban
Elafibranor
Elagolix
Elbasvir
Eletriptan
Elexacaftor
Emapalumab
Enalapril
Enalapril
Enalaprilat
Enalaprilat
Encorafenib
Enfortumab vedotin
Enzalutamide
Epcoritamab
Epinastine
Epinephrine
Epinephrine
Eplerenone
Eprosartan
Eravacycline
Erdafitinib
Ertugliflozin
Ertugliflozin
Erythromycin
Escitalopram
Escitalopram
Esketamine
Eslicarbazepine acetate
Esomeprazole
Estazolam
Esterified estrogens
Estetrol
Estetrol
Estradiol
Estradiol
Estradiol acetate
Estradiol cypionate
Estradiol valerate
Estrone sulfate
Estrone sulfate
Eszopiclone
Etacrynic acid
Etanercept
Ethanol
Ethanol
Ethinylestradiol
Ethinylestradiol
Ethosuximide
Ethosuximide
Ethynodiol diacetate
Ethynodiol diacetate
Etonogestrel
Etonogestrel
Etrasimod
Etravirine
Everolimus
Everolimus
Exemestane
Exenatide
Exenatide
Famotidine
Fedratinib
Felbamate
Felodipine
Felodipine
Fenofibrate
Fentanyl
Fesoterodine
Fexinidazole
Fexofenadine
Finasteride
Finerenone
Fish oil
Fluconazole
Fluconazole
Fludrocortisone
Fludrocortisone
Flunisolide
Flunisolide
Fluocinolone acetonide
Fluocinolone acetonide
Fluocinonide
Fluocinonide
Fluorometholone
Fluorometholone
Fluoxetine
Fluoxetine
Flurandrenolide
Flurandrenolide
Flurazepam
Flutamide
Fluticasone furoate
Fluticasone furoate
Fluticasone propionate
Fluticasone propionate
Fluvastatin
Fluvoxamine
Fluvoxamine
Formoterol
Fosamprenavir
Fosamprenavir
Fosaprepitant
Fosinopril
Fosinopril
Fosnetupitant
Fosphenytoin
Fostamatinib
Fostemsavir
Fruquintinib
Furosemide
Fusidic acid
Futibatinib
Galantamine
Ganciclovir
Gatifloxacin
Gatifloxacin
Gefitinib
Gemfibrozil
Gemifloxacin
Gemifloxacin
Genistein
Gepirone
Gepotidacin
Gestodene
Gilteritinib
Glasdegib
Glecaprevir
Glimepiride
Glimepiride
Glipizide
Glipizide
Glofitamab
Glyburide
Glyburide
Glycerol phenylbutyrate
Golimumab
Goserelin
Goserelin
Granisetron
Grapefruit
Grazoprevir
Griseofulvin
Guanfacine
Guanidine
Halcinonide
Halcinonide
Haloperidol
Haloperidol
Histamine
Histrelin
Histrelin
Hydralazine
Hydrochlorothiazide
Hydrocodone
Hydrocortisone
Hydrocortisone
Hydrocortisone acetate
Hydrocortisone acetate
Hydrocortisone butyrate
Hydrocortisone butyrate
Hydrocortisone probutate
Hydrocortisone probutate
Hydrocortisone succinate
Hydrocortisone succinate
Hydrocortisone valerate
Hydrocortisone valerate
Hydroflumethiazide
Hydroxychloroquine
Hydroxychloroquine
Hydroxyprogesterone caproate
Hydroxyprogesterone caproate
Hydroxyzine
Ibrexafungerp
Ibrutinib
Ibuprofen
Icatibant
Iloperidone
Iloperidone
Imatinib
Imipramine
Indapamide
Indinavir
Indomethacin
Indomethacin
Infliximab
Insulin aspart
Insulin aspart
Insulin degludec
Insulin degludec
Insulin detemir
Insulin detemir
Insulin glargine
Insulin glargine
Insulin glulisine
Insulin glulisine
Insulin human
Insulin human
Insulin lispro
Insulin lispro
Ipecac
Irbesartan
Isavuconazonium
Isocarboxazid
Isoniazid
Isoniazid
Isotretinoin
Isradipine
Isradipine
Istradefylline
Ivacaftor
Ivermectin
Ivosidenib
Ketamine
Labetalol
Labetalol
Lacosamide
Lamivudine
Lamotrigine
Lanreotide
Lanreotide
Lansoprazole
Lapatinib
Larotrectinib
Lasmiditan
Lazertinib
Ledipasvir
Lefamulin
Lemborexant
Lenacapavir
Lenvatinib
Letermovir
Letrozole
Leuprolide
Leuprolide
Levamlodipine
Levamlodipine
Levocetirizine
Levofloxacin
Levofloxacin
Levomenthol
Levomilnacipran
Levomilnacipran
Levonorgestrel
Levonorgestrel
Lidocaine
Linezolid
Liothyronine
Liothyronine
Lipoic acid
Lipoic acid
Liraglutide
Liraglutide
Lisinopril
Lisinopril
Lixisenatide
Lixisenatide
Lomefloxacin
Lomefloxacin
Lonapegsomatropin
Lonapegsomatropin
Loncastuximab tesirine
Lopinavir
Loratadine
Lorlatinib
Losartan
Lovastatin
Loxapine
Lumacaftor
Lumateperone
Lumefantrine
Lurasidone
Lurasidone
Lurbinectedin
Lusutrombopag
Macimorelin
Macitentan
Magnesium sulfate
Magnesium sulfate
Mannitol
Maraviroc
Maribavir
Mavacamten
Mavorixafor
Mecasermin
Mecasermin
Medroxyprogesterone acetate
Medroxyprogesterone acetate
Medrysone
Medrysone
Mefloquine
Megestrol acetate
Megestrol acetate
Meloxicam
Memantine
Meperidine
Mesalazine
Mesalazine
Methadone
Methohexital
Methsuximide
Methsuximide
Methyl salicylate
Methyl salicylate
Methylene blue
Methylene blue
Methylergometrine
Methylprednisolone
Methylprednisolone
Methylprednisolone hemisuccinate
Methylprednisolone hemisuccinate
Methyltestosterone
Metoclopramide
Metolazone
Metoprolol
Metoprolol
Metronidazole
Metyrapone
Mexiletine
Miconazole
Midazolam
Mifepristone
Mifepristone
Miglitol
Miglitol
Milnacipran
Milnacipran
Mirabegron
Mirtazapine
Mitapivat
Modafinil
Moexipril
Moexipril
Mometasone furoate
Mometasone furoate
Montelukast
Morphine
Moxifloxacin
Moxifloxacin
Mycophenolate mofetil
Nabilone
Nadolol
Nadolol
Nafcillin
Naloxegol
Nateglinide
Nateglinide
Nebivolol
Nebivolol
Nefazodone
Nelfinavir
Netupitant
Nevirapine
Niacin
Niacin
Nicardipine
Nicardipine
Nicotine
Nifedipine
Nifedipine
Nilotinib
Nimodipine
Nimodipine
Nintedanib
Nirmatrelvir
Nirogacestat
Nisoldipine
Nisoldipine
Norelgestromin
Norepinephrine
Norethisterone
Norethisterone
Norgestimate
Norgestimate
Norgestrel
Nortriptyline
Octreotide
Octreotide
Ofloxacin
Ofloxacin
Olanzapine
Olanzapine
Olaparib
Oliceridine
Olsalazine
Olsalazine
Olutasidenib
Omadacycline
Ombitasvir
Ondansetron
Opium
Oritavancin
Orphenadrine
Osilodrostat
Ospemifene
Oxcarbazepine
Oxybutynin
Oxycodone
Oxymorphone
Paliperidone
Paliperidone
Palonosetron
Palovarotene
Pancuronium
Pantoprazole
Parecoxib
Paricalcitol
Paritaprevir
Paroxetine
Paroxetine
Pasireotide
Pasireotide
Pazopanib
Pegvisomant
Pegvisomant
Pemigatinib
Pentamidine
Pentamidine
Pentobarbital
Perampanel
Perindopril
Perindopril
Phenelzine
Phenobarbital
Phenoxybenzamine
Phentermine
Phentermine
Phenytoin
Phenytoin
Pibrentasvir
Pinaverium
Pinaverium
Pindolol
Pindolol
Pioglitazone
Pioglitazone
Piperine
Pirtobrutinib
Pitolisant
Polatuzumab vedotin
Polythiazide
Ponesimod
Pralsetinib
Pramipexole
Pramlintide
Pramlintide
Prasterone
Pravastatin
Praziquantel
Prazosin
Prednicarbate
Prednicarbate
Prednisolone
Prednisolone
Prednisolone acetate
Prednisolone acetate
Prednisolone phosphate
Prednisolone phosphate
Prednisone
Prednisone
Pregabalin
Pregabalin
Pregnenolone
Primaquine
Primidone
Probenecid
Procaine
Procarbazine
Prochlorperazine
Progesterone
Progesterone
Propafenone
Propafenone
Propranolol
Propranolol
Protriptyline
Protriptyline
Prucalopride
Pseudoephedrine
Pseudoephedrine
Quazepam
Quetiapine
Quetiapine
Quinapril
Quinapril
Quinine
Quinine
Quizartinib
Raloxifene
Ramelteon
Ramipril
Ramipril
Ranitidine
Ranolazine
Rasagiline
Relugolix
Remdesivir
Repaglinide
Repaglinide
Repotrectinib
Reserpine
Retapamulin
Revefenacin
Revumenib
Rifabutin
Rifampin
Rifaximin
Rilonacept
Rilpivirine
Riociguat
Ripretinib
Risperidone
Ritlecitinib
Ritonavir
Ritonavir
Rivaroxaban
Rocuronium
Roflumilast
Rolapitant
Rosiglitazone
Rosiglitazone
Rosuvastatin
Rotigotine
Rucaparib
Rufinamide
Sacubitril
Safinamide
Safinamide
Salicylic acid
Salicylic acid
Salmeterol
Samidorphan
Sapropterin
Saquinavir
Sarecycline
Sarilumab
Satralizumab
Saxagliptin
Saxagliptin
Scopolamine
Secobarbital
Secobarbital
Secukinumab
Selegiline
Selegiline
Selexipag
Selinexor
Selpercatinib
Semaglutide
Semaglutide
Sertraline
Sertraline
Sildenafil
Siltuximab
Simvastatin
Sirolimus
Sitagliptin
Sitagliptin
Sodium ferric gluconate complex
Sofosbuvir
Solifenacin
Solriamfetol
Somapacitan
Somapacitan
Somatotropin
Somatotropin
Somatrogon
Somatrogon
Sonidegib
Sotagliflozin
Sotagliflozin
Sotalol
Sotalol
Sotorasib
Sparsentan
Stiripentol
Sufentanil
Sulfadiazine
Sulfadiazine
Sulfamethoxazole
Sulfamethoxazole
Sulfasalazine
Sulfasalazine
Sunitinib
Suvorexant
Suzetrigine
Synthetic Conjugated Estrogens, A
Synthetic Conjugated Estrogens, B
Tacrolimus
Tacrolimus
Tadalafil
Tafenoquine
Tamsulosin
Tasimelteon
Tazemetostat
Technetium Tc-99m sestamibi
Tecovirimat
Tegaserod
Telmisartan
Telotristat ethyl
Temsirolimus
Tenecteplase
Tenofovir alafenamide
Tenofovir disoproxil
Teprotumumab
Teprotumumab
Terbinafine
Testosterone
Testosterone cypionate
Testosterone enanthate
Testosterone propionate
Tetracycline
Tezacaftor
Thalidomide
Thiamine
Thyroid, porcine
Thyroid, porcine
Thyrotropin alfa
Thyrotropin alfa
Tiagabine
Ticagrelor
Timolol
Timolol
Tinidazole
Tiotropium
Tipranavir
Tipranavir
Tirzepatide
Tirzepatide
Tisotumab vedotin
Tivozanib
Tixocortol
Tixocortol
Tocilizumab
Tocofersolan
Tocopherol
Tofacitinib
Tolazamide
Tolazamide
Tolterodine
Topiramate
Topotecan
Torasemide
Toremifene
Tovorafenib
Tramadol
Trandolapril
Trandolapril
Tranylcypromine
Trazodone
Treosulfan
Tretinoin
Triamcinolone
Triamcinolone
Triazolam
Triclabendazole
Trilaciclib
Trimethoprim
Trimipramine
Triptorelin
Triptorelin
Trolamine salicylate
Trolamine salicylate
Trovafloxacin
Trovafloxacin
Tucatinib
Ubidecarenone
Ubidecarenone
Ubrogepant
Ulipristal
Ulobetasol
Ulobetasol
Umeclidinium
Upadacitinib
Urokinase
Valbenazine
Valdecoxib
Valproic acid
Valsartan
Vamorolone
Vamorolone
Vardenafil
Velpatasvir
Vemurafenib
Venlafaxine
Venlafaxine
Verapamil
Verapamil
Vilanterol
Vilazodone
Vimseltinib
Vincristine
Vitamin D
Vitamin E
Voclosporin
Vonoprazan
Vorapaxar
Vorasidenib
Vorinostat
Vorinostat
Vortioxetine
Voxelotor
Voxilaprevir
Warfarin
Xylometazoline
Xylometazoline
Zafirlukast
Zaleplon
Zanubrutinib
Ziconotide
Ziconotide
Zidovudine
Zileuton
Ziprasidone
Ziprasidone
Zolpidem
Zonisamide
Zuranolone
Abaloparatide
Acetazolamide
Acetyl sulfisoxazole
Acetyl sulfisoxazole
Albuterol
Albuterol
Aldesleukin
Aliskiren
Ambrisentan
Amifostine
Amiloride
Amphotericin B
Amyl Nitrite
Apomorphine
Aprocitentan
Arimoclomol
Aripiprazole lauroxil
Avanafil
Azilsartan medoxomil
Bendroflumethiazide
Bosentan
Bretylium
Brinzolamide
Bromotheophylline
Bumetanide
Bupivacaine
Candesartan cilexetil
Celecoxib
Chlorothiazide
Chlorthalidone
Clofarabine
Clonidine
Conivaptan
Dalfopristin
Dasiglucagon
Desflurane
Dexmedetomidine
Diclofenamide
Diclofenamide
Dinutuximab
Dipyridamole
Dorzolamide
Doxazosin
Drospirenone
Duloxetine
Ensartinib
Eplerenone
Epoprostenol
Eprosartan
Esmolol
Etacrynic acid
Ethambutol
Fedratinib
Fenoldopam
Finerenone
Fluoxymesterone
Fluoxymesterone
Fostamatinib
Furosemide
Ginkgo biloba
Guanfacine
Hydralazine
Hydrochlorothiazide
Hydroflumethiazide
Iloprost
Indapamide
Irbesartan
Isocarboxazid
Isoflurane
Isosorbide
Isosorbide dinitrate
Isosorbide mononitrate
Isoxsuprine
Ketotifen
Ketotifen
L-Acetylleucine
Landiolol
Levodopa
Levothyroxine
Levothyroxine
Linezolid
Lithium carbonate
Lithium carbonate
Lofexidine
Loperamide
Losartan
Macitentan
Mannitol
Mecamylamine
Methazolamide
Methazolamide
Methyldopa
Methyltestosterone
Metolazone
Metreleptin
Metyrosine
Minoxidil
Mitapivat
Morphine
Nabilone
Nandrolone decanoate
Nandrolone decanoate
Nitric Oxide
Nitroglycerin
Nitroprusside
Nitrous acid
Obinutuzumab
Olmesartan
Opicapone
Oxandrolone
Oxandrolone
Oxymetholone
Oxymetholone
Paclitaxel
Papaverine
Phenelzine
Phenoxybenzamine
Phentolamine
Polythiazide
Potassium
Potassium cation
Potassium citrate
Pramipexole
Prazosin
Probenecid
Procaine
Procarbazine
Propofol
Propofol
Quinupristin
Rasagiline
Remifentanil
Reserpine
Riociguat
Risperidone
Ropinirole
Ropivacaine
Rosuvastatin
Rotigotine
Sacubitril
Selexipag
Sevoflurane
Sildenafil
Sotatercept
Spironolactone
Sufentanil
Sulfamethizole
Sulfamethizole
Sumatriptan
Sumatriptan
Tadalafil
Talazoparib
Tamsulosin
Telmisartan
Terazosin
Testosterone
Testosterone cypionate
Testosterone enanthate
Testosterone propionate
Testosterone undecanoate
Testosterone undecanoate
Thalidomide
Thioridazine
Tipiracil
Tizanidine
Tocopherylquinone
Tolcapone
Tolvaptan
Torasemide
Tranylcypromine
Treprostinil
Triamterene
Trofinetide
Vadadustat
Valdecoxib
Valsartan
Vardenafil
Varenicline
Vemurafenib
Vericiguat
Viloxazine
Zonisamide